AccessPaL – MPP’s Access pathways and landscape tracker

AccessPaL (Access pathways and landscape tracker) is an interactive tool that provides an overview of the availability and rollout of MPP‑licensed medicines. Through quarterly data collection, it tracks the progress of generic partners in developing, filing and supplying these products in countries where access would otherwise not have been possible, alongside key information on patent and licensing status.

The tool features:

• An interactive map (click here to view full size) with three tabs:
  • Product availability through MPP licences, showing where products are filed, approved or supplied, with timelines and product-level details
  • Patent and licensing status, based on data from MedsPaL, covering product status by country and region
  • Disease burden (HIV), presenting prevalence and number of people living with HIV using UNAIDS data
• An interactive table (click here to view full size) tracking the progress of generic partners, including regulatory submissions, approvals and supply readiness

The map and table are updated quarterly  following MPP’s quarterly review meetings (QRMs) with generic partners, while a biannual slide deck provides a consolidated overview of progress.

Download the slide deck (PDF)

*[WHO-PQ] Prequalification from the World Health Organization (WHO) | **[USFDA] U.S. Food and Drug Administration | ***[ERP] Expert Review Panel hosted by the Quality and Safety of Medicines department of the WHO and making recommendations to the Global Fund | Temporary approval through the ERP, valid for one year, is permitted where WHO-PQ or USFDA approval are not yet available. This does not apply to products under licences with Gilead Sciences (those licences do not accept ERP) | ****[Other SRA’s/WLA’s] Refers to Stringent Regulatory Authority other than USFDA and/or WHO-Listed Authorities.

> Interactive map:
– Patent and licensing status: last updated in May 2026;
– Product availability data from MPP sublicensees: last updated in March 2026 (data as of December 2025) Disclaimer

> Interactive table: last update in March 2026 (data as of December 2025)

Note: Sales may occur in countries in the absence of registration via procurement channels, registration waivers and/or exemptions.